Crescendo Biologics Appoints Chair

17 Nov 2015

• By Lubna Ahmed

Crescendo Biologics Ltd. has appointed Kevin Johnson non-executive chair of the board of directors – effective immediately. Johnson has 27 years' experience in antibody development and previously was CEO of Netherlands-based PanGenetics, an antibody development company. He also held various roles at Cambridge Antibody Technology, which eventually led to his appointment as research director and chief technology officer. Since 2003 he has been working in the life science team at Index Ventures.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

09 Jul 2025

• By Kevin Grogan

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

09 Jul 2025

• By Anju Ghangurde

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

09 Jul 2025

• By Andrew McConaghie

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.